Joseph Charalel
Vice President at Pivotal bioVenture Partners
Stanford, California
Overview
Work Experience
Investor
2025 - Current
Biotech
Vice President
2024 - 2025
• Lead diligence on and help source new investment deals (Seed, Series A, B, C, PIPEs and public market purchases) • Support portfolio companies as a Board Observer. Work with management teams to refine company strategy and investment pitches for new financings. Held Board Observer seats at: Evommune, Avalyn Pharma, Fountain Therapeutics, Aptihealth, Encodia • Manage positions in public biotech portfolio companies including fundamental research, valuation, and investment recommendations • Aid strategic planning and provide UX feedback for firm’s data science effort; my work primarily focuses on business objectives, methods, data sources, and user experience
Senior Associate
2022 - 2023
Guest Lecturer
2023 - 2024
• Guest lecturer on valuation methodology - INDE 209: Analysis of Public Companies in the Life Sciences
Manager
2020 - 2021
• Experience driving cases across private equity, customer experience, healthcare, banking • Led teams on 15 total diligences across technology and healthcare sectors (mix of growth stage and LBO targets) including revenue projections, market outlook (TAM/SAM, overall market growth), competitive landscape analysis, and post-acquisition strategy for investor clients • Supported and trained junior consultants with increasing responsibility
Consultant
2018 - 2020
General Partner
2017 - 2018
• Equity partner and manager in small-cap biotech fund led by Stanford trainees
PhD Candidate in Genetics
2013 - 2018
• Perform research in the laboratory of Dr. Christina Curtis on the genetic and epigenetic basis of drug resistance in HER2+ breast cancers via multi-omic profiling. Focus on using genome-wide sequencing assays and machine learning to understand drug response using in vitro model systems and patient data. (2015-Present) • Researcher in the laboratory of Dr. Atul Butte (now at UCSF). Worked on in silico characterization of cancer cell lines as tumor models using publicly available omics data. (2014-2015)
Intern
2017 - 2018
• Performed due diligence to identify potential new investment opportunities and develop comprehensive thesis for a particular therapeutic area • Contributed to company analysis efforts which led to investment decisions • Led key opinion leader calls, analyzed primary research literature, analyst reports to develop comprehensive commercial and scientific view of the key opportunities in the space • Synthesized and presented findings to Longitude leadership
Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Consultant Intern
2017 - 2017
• Worked on agile transformation project for top ten pharmaceutical client • Accepted full time offer for 2018 consultant class in SF office
Research Assistant
2010 - 2013
• Performed research in the laboratory of Dr. Liza Pon on the role and mechanisms of mitochondrial dynamics (anchorage, fusion, and fission) in cellular aging to better understand human age-related diseases • Initiated new project defining the role of mitochondrial fusion and fission in mitochondrial inheritance • Supervised and mentored three undergraduate students • Established new techniques in the lab through literature search and new partnerships • Co-authored 3 papers (listed below)
Columbia University Irving Medical Center is a clinical and educational enterprise that offers medical, dental, and nursing services.
Analyst Intern
2008 - 2008
• Synthesized research from secondary sources and investor conferences to contribute to investment decisions for a long-short equity hedge fund with ~$500M AUM